The Effect of Chemical Modifications of Chitosan on Intestinal Permeability and Oral Bioavailability of Carbamoylphosphonate JS403

Reut Bitton-Dotan¹, Joerg Bohrisch², Christian Schmidt², Marina Tsuriel¹, RN Prasad Tulichala¹, Eli Breuer¹, Reuven Reich¹, Amnon Hoffman¹*, Joachim Storsberg²

¹Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 91120, Israel; ²Fraunhofer Institute Applied Polymer Research (IAP), Department of Biomaterials & Healthcare, Geiselbergstrasse 69, 14476 Potsdam, Germany

ABSTRACT
JS403, Carbamoylphosphonate molecule, is a promising drug candidate with anti-metastatic activity. The polarity and water solubility of JS403 evolve from the phosphonate moiety that is ionized at physiologic pH. JS403 is regarded as a BCS class III molecule, and exhibit poor absolute oral bioavailability of less than 1%. The aim of this investigation is to identify proper chitosan based absorption enhancer compound(s) that upon oral co-administration with JS403 which would enhance its bioavailability. To determine the optimal properties of the chitosan derivative (CD), 11 relevant compounds were synthesized, each with different attribute, and their impact on the intestinal permeability of JS403 was examined in-vitro using the Caco-2 monolayer model. Then, the oral bioavailability of JS403 coadministered with the selected CD was examined in the freely moving rat model. The in-vitro study identified two leading trimethyl CD, KC13, (85% deacetylation, MW 20,000 gr/mol and 66% trimethylation) and a novel derivative of hydroxypropyl chitosan KHC2 (trimethylation 71%) increased JS403 permeability in 2 and 10 folds, respectively. Similar permeability results were obtained when the same chitosan derivatives were coadministered with atenolol, another BSCIII drug. The paracellular absorption mechanism of these BCS III compounds was ascertained using palmitoyl carnitine as positive control. The pharmacokinetic investigation, following gavage co-administration with either KC13 or KHC2, showed a significant increase in JS403 oral AUC of 200%. The in-vitro permeation data correlated with the oral bioavailability outcomes. The relatively modest enhancement (~2 folds) of the chitosan derivatives in-vivo is anticipated as their effect on the enterocytes integrity and tight junction (TJ) need to be moderate. This is required because their noninvasive and reversible impact that is demanded in case of multiple treatment.

Keywords: Absorption enhancer; Intestinal permeability; Pharmaceutical approach; Oral bioavailability; BCS Class III; Chitosan derivatives; Paracellular; Palmitoyl carnitine

INTRODUCTION
JS403 is a small carbamoylphosphonates (CPO) molecule, with a structure of sulfonamide moiety and chain of 6 methylene that link the anionic phosphonate moiety (Figure 1). JS403 in an important compound as it was shown to inhibit the activity on three cancer promoting zinc-enzyme: matrix metalloproteinase (MMP-II), carbonic anhydrase 9 and 12 (CA-IX, CA-XII) and autotaxin (ATX) [1]. Furthermore, in-vivo studies in murine melanoma models of B16F10 injection have shown promising results of 71 percent decrease in lung metastasis following JS403 oral administration [2]. Those figures pose JS403 as a promising drug candidate for anti-metastasis. A key factor for JS403 as a drug candidate is the fact that it is ionized to anion in all physiological pH and for that reason cannot penetrate via cells membrane [1]. Therefore, JS403 hardly cross the intestinal wall, and once in the body its volume of distribution is restricted to the extracellular fluid. It is fortunate that the active sites of the relevant zinc-enzymes involved in metastases progression are distinctively exposed to the extracellular fluids. The restriction of the volume of distribution of JS403 is also important fact in lowering its potential intracellular associated toxicity [1].

Correspondence to: Amnon Hoffman, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 91120, Israel, Tel: 97226757014; E-mail: amnonh@ekmd.huji.ac.il

Received: February 26, 2020, Accepted: March 31, 2020, Published: April 07, 2020


Copyright: © Bitton-Dotan R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
JS403 is characterized by high water solubility and low membrane permeability therefore is considered as Biopharmaceutics Classification System (BSC) class III molecule [3]. The intestinal permeability of class III molecules is mainly limited to paracellular pathway. This pathway consists of diminutive surface area of the tight junctions (TJ) - less than 0.1% of the total intestinal epithelial layer surface [4]. Hence, the low oral availability of less than 1% of JS403 limit its development toward becoming clinically useful medication against metastasis in cancer patients [2]. This is particularly important since JS403 is intended to be taken daily as a preventative anti-metastatic treatment. Thus, to ensure good patient compliance and comfort, the route of administration should be oral with reliable oral absorption.

A major strategy in overcoming the restricted bioavailability is the "pharmaceutical approach" of coadministration of the active pharmaceutical ingredient (API) with absorption enhancer(s) that modulate the opening. However, it is important to note that affecting the TJ opening should be in a noninvasive and reversible manner. Therefore, their expected impact is limited to relatively modest magnitude of effect.

To achieve this goal of elevating the JS403 oral bioavailability, a wide library of 11 trimethyl chitosan (TMC) derivatives were synthesized in this investigation. Chitosan was selected based on previous reports that implied their impact on enhancing the paracellular pathway (Figure 2). Chitosan is a biocompatible polymer with promising reversible tight junction modulating properties mainly by means of epithelial mucoadhesion [5,6]. However, a major drawback of the non-derived chitosan is its solubility that is limited to acidic environment [7]. Therefore, chitosan derivatives were generated, primarily TMC (Figure 3), which showed significant permeation enhancement and no apparent cytotoxic effect for mannitol an hydrophilic API that has been commonly used as a model drug to evaluate paracellular permeation kinetics [8].

In order to determine the greatest impact on the TJ and on JS403 intestinal permeability, the effect of the different TMC derivatives has been investigated. All derivatives possess certain different parameter in different degrees and ranges in order to enable intelligent selection of the superior derivation. The parameters which have been studied are molecular weight in range of 104 to 106 (MW), deacetylation with 85% and 95% degree and trimethylation within range of 32%-71%. Following the knowledge obtained by identifying the optimal parameters from the tested chitosans, a novel library of N-methylated hydroxypropyl chitosan (KHC) derivatives (Figure 4) has been designed. This new derivative contributed the element of increased lipophilicity and its impact on JS403 intestinal permeability and oral bioavailability was established.

JS403 is negatively charged in physiological fluids thus may represent certain anionic BCS III APIs. In order to reach a broader conclusion for BCS III absorption enhancers, additional class III drug, atenolol (Figure 5) was used as model API and given together with the leading TMC derivatives in the Caco-2 permeability studies. Atenolol is a known low permeability marker and in contrast to JS403, it is a basic drug with pKa= 9.5 that has positive charge at physiological conditions [9]. These two molecules differ profoundly in their physico-chemical properties. Thus, the comparison between the impact of the co-administered chitosan derivatives on the intestinal permeability of these two BCS III compounds, under similar experimental conditions, widen the understanding of this approach and enables to derive more sound conclusions.

The direct influence of TMC derivatives on JS403 permeability enhancement were assessed first by in-vitro model at cell monolayer Caco-2 (mimic enterocytes layer). The outcomes of these studies paved the ground for in-vivo PK studies in the freely moving rat model that provides direct information on oral bioavailability of the tested API, which was the ultimate goal of this investigation. Caco-2 is regarded as good predictor for intestinal permeability process [10].

Another known powerful enhancer for intestinal permeability is palmitoyl carnitine (PC). PC is a robust TJ modulator that when apply with BCS III medication in Caco2 model increase the permeability. Therefore, PC were used as a positive control for comparing the other potentially absorption enhancers examined for hydrophilic molecules. However, its activity showed lytic effect with a decline in cell viability [11]. Since the use in enhancer required safety, PC cannot be used as enhancer. At this study, PC was used...
as a positive control for the permeability modification imposed by the examined TMC derivatives as a paracellular enhancer.

Ultimately, since the main goal of this study was to reveal a proper uptake enhancer for JS403 which will promote its development toward clinical utilization, the effect on JS403 oral bioavailability was assessed in the freely moving rat model taking into considerations the outcomes of the in-vitro permeability studies.

MATERIALS AND METHODS

Chemicals

All materials, unless otherwise stated, were purchased from Sigma Aldrich (Rehovot, Israel).

Synthesis

JS403 was synthesized by Prof. Eli Breuer's laboratory, Institute for Drug Research, Hebrew University, Jerusalem, Israel. The N-trimethyl and hydroxypropyl N-trimethyl chitosan were synthesized by Dr. Joachim Storsberg's laboratory, Fraunhofer-Institute für Angewandte Polymerforschung IAP, Potsdam, Germany.

N-trimethyl chitosan synthesis details

The library of TMCs (Table 1) was synthesized adapting a known procedure [Sieval, A.B., Thanou, M., Kotze, A.F., Verhoef, J.C., Brusee, J., Junginger, H.E. Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydrate polymers 36, 157-165 (1998)].

Step 1 (KC21 + KC41): In a 2 l 3-necked flask 25 g (150 mmol) of chitosan (50K), 60 g of NaI and 138 mL of aqueous NaOH (15%) were dissolved in 1000 mL of N-methylpyrrolidone. The mixture was heated to 60°C for 1 hour. With stirring, 326.4 g (2.3 mol) of iodomethane were added dropwise via dropping funnel. After 1 h, the light-yellow solution was precipitated in 6 l of ethanol and the flocculent precipitate was centrifuged off for 5 min at 4000 min⁻¹. Then this was washed twice with diethyl ether (G1 frit) and dried in vacuum overnight. The I-/Cl⁻ exchange was performed by.

Dissolving performed by dissolving the polymer in 200 mL NaCl solution (10%) overnight. The solution was filtered again and then dialysed (5 days, 14 kD) and freeze-dried. The H-nmr analysis revealed a ratio quaternary/tertiary amino group of 32/53 in case of KC21 and of 33/62 in case of KC41 [1].

Step 2 (KC22 + KC42): In the same manner as above 44 g of the solid (step 1, ahead of anion exchange) were mixed with 40 g NaI and 92 mL of aqueous NaOH (15%) in 660 mL of N-methylpyrrolidone and reacted with 132.2 g of iodomethane. Usual workup with anion exchange yielded a polymer with ratio quaternary/tertiary amino group of 57/23 in the case of KC23 and 79/16 in the case of KC43.

Step 3 (KC23 + KC43): In the same manner as above 18.4 g of the solid (step 2, ahead of the anion exchange) were dissolved in 330 mL of N-methylpyrrolidone together with 2.5 g of solid NaOH and reacted with 18.9 g of iodomethane. Usual workup with anion exchange yielded a polymer with ratio quaternary/tertiary amino group of 57/23 in the case of KC23 and 79/16 in the case of KC43.

The 20K Chitosan (85 and 95% deacetylation degree) was reacted in the same way. Products of step 1 (KC31) with a ratio quaternary/tertiary (q/t) amino group of 38/57, step 2 (KC12) with a ratio q/t amino group of 52/33 and of step 3 (KC13) with a ratio q/t amino group of 66/19 were taken for further investigation.

Hydroxypropyl N-trimethyl chitosan Synthesis details


In a 250 mL 3-necked flask 7 g (42 mmol) of chitosan (20K) were mixed with 35 mL aqueous NaOH (13%) and stirred for 2 hours. After freezing overnight at -18 °C the mixture was thawed and 56 g (0.96 mol) of propylene oxide were added. The mixture was stirred and refluxed at 40°C for 30 min. The hydroxypropyl chitosan (substitution degree according to 1H-nmr was ~0.9) obtained after dialysis (5 days, 3.5 kD) was taken for the next steps.

Step 2 (KHC1): In a 250 mL 3-necked flask 4.4 g of this material were mixed with 10 g NaI and 22.6 mL aqueous NaOH (15%) in 160 mL N-methylpyrrolidone. The mixture was heated to 60°C. With stirring, 53.4 g of iodomethane were added dropwise via dropping funnel. After 1 hour the mixture was precipitated in 1.6 l of ethanol. The flocculent precipitate was filtered (G3 frit), washed three times with diethyl ether (G1 frit). The I-/Cl⁻ exchange was performed by dissolving the polymer in 150 mL NaCl solution (10%) overnight. The solution was dialysed (5 days, 3.5 kD) and freeze-dried. The 1H-nmr analysis revealed a ratio quaternary/tertiary amino group of 42/43, assuming no N-hydroxypropylation.

Step 3 (KHC2): In the same manner 2.2 g of the precipitate of step 2 were mixed with 5 g NaI and 11 mL aqueous NaOH (15%) in 80 mL N-methylpyrrolidone and reacted with 16 g iodomethane. Usual workup with anion exchange yielded a polymer with ratio quaternary/tertiary amino group of 71/14, assuming no N-hydroxypropylation.

In-vitro permeability studies: Caco-2 and cell model

Caco-2 cell monolayer assay

Growth and maintenance of cells: Caco-2 cells were obtained from ATCC (Manassas, VA, USA) and then grown in 75 cm² flasks at 37°C in 5% CO₂ atmosphere and a relative humidity of 95%. The culture growth medium consisted of Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% nonessential amino acids, 2 mM L-glutamine, 2 mM sodium pyruvate and 2 mM penicillin-streptomycin solution.

Preparation of cells for transport studies: Cells in a passage

Table 1: Chitosan’s examined in Caco-2 study.

<table>
<thead>
<tr>
<th>Chitosan Name</th>
<th>Molecular Weight (g/mol)</th>
<th>Degree of Deacetylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Molecular Weight</td>
<td>70,000</td>
<td>80</td>
</tr>
<tr>
<td>Medium Molecular Weight</td>
<td>750,000</td>
<td>80</td>
</tr>
<tr>
<td>High Molecular Weight</td>
<td>2,000,000</td>
<td>80</td>
</tr>
</tbody>
</table>

J Bioequiv Availab, Vol. 12 Iss. 2 No: 392
range of 52-60 were seeded at a density of 25-105 cells/cm² on untreated culture inserts of polycarbonate membrane with 0.4 μm pores and a surface area of 1.1 cm². The culture inserts containing the Caco-2 monolayer were placed in 24 trans-well plates 12 mm, Costar. The culture medium was replaced every other day. Transport studies were performed 21-23 days after seeding, when the cells were fully differentiated and the TEER values were stable (300-500 Ω cm²).

Transport experiment protocol for Caco-2: Transport study (apical to basolateral, A to B) was initiated by medium removal from both sides of the monolayer and replacement with 600 μL apical buffer (0.025M D-glucose monohydrate, 0.02 M MES biological Buffer, 1.25 mM calcium chloride and 0.5mM magnesium chloride in Hanks Balanced Salt Solution, filtered and titrated to pH 6.5 with NaOH) and 1500 μL basolateral buffer (0.025M D-glucose monohydrate, 0.02 M HEPES biological Buffer, 1.25mM calcium chloride, and 0.5mM magnesium chloride in Hanks Balanced Salt Solution, filtered and titrated to pH 7.4 with NaOH), both warmed to 37°C. The cells were incubated for 30 min at 37°C with shaking (100 cycles/min). Test solutions were dissolved in apical buffer and preheated to 37°C and added (600 μL) to the apical side of the monolayer. (In Chitosan private case, to ensure that the chitosan will dissolve freely in the buffer, the pH was adjusted to pH=5.5, according to a published protocol [6]. Model compound, JS403, apparent permeability was also assessed the same pH to ensure monolayer viability throughout the experiment. The rest of the protocol was carried out as explained in this section.) 50 μL samples were taken from the apical side immediately at the beginning of the experiment, resulting in 550 μL apical volume during the experiment. For the period of the experiment, cells were kept shaken at 37°C. At certain predetermined times (20, 40, 60, 80, 100, 120 and 150 min), 200 μL samples were taken from the basolateral side and replaced with the same volume of fresh basolateral buffer to maintain a constant volume.

Data analysis: The permeability enhancers (Papp) for JS403 and atenolol were calculated using the following equation:

\[ P_{app} = \frac{dQ}{dt} \times \frac{1}{A} \times \frac{1}{C_0} \]

where \( dQ/dt \) is the steady state rate of appearance of the drug on the receiver side (obtained from the linear plot of drug accumulated vs. time), \( C_0 \) is the initial concentration of the drug on the donor side, and \( A \) is the surface area available for permeation [12].

In-vivo pharmacokinetic studies

Male Wistar rats (275 - 300 g) were purchased from Harlan laboratories (Rehovot, Israel). All rats receive free access to food and water up to three hours before the experiment. All surgical and experimental procedures were reviewed and approved by the Animal Experimentation Ethics Committee of the Hebrew University Hadassah Medical Center, Jerusalem. In order to enable convenient blood sampling, an indwelling cannula was implanted into the right jugular vein 24 hours before the pharmacokinetic experiment as described before [13]. During the cannula implantation rats were anesthetized by intra-peritoneal injection of 1 mL/kg of ketamine-xylazoline solution (9:1, respectively). The cannula was tunneled beneath the skin and exteriorized at the dorsal part of the neck. After completion of the surgical procedure, the animals were kept overnight in individual cages. Four hours post oral administration free access to food and water was available. Animals were randomly assigned to the different experimental groups. JS403 formulation solution of (30 mg/mL) was freshly prepared prior to administration with 300 mg/kg of JS403 and 100 mg/kg dose for chitosan derivatives. The solutions administered by using oral gavage to the rats (n=4). After dosing blood samples of 300 μL were taken at 0, 0.16, 0.5, 1, 3, 6, 10, 24h, 36, and 48 h post-dosing. Equal volumes of heparinized saline were administered after each blood sampling. Plasma samples were separated by centrifugation (4g, 10 min, and 4°C) and stored at -20°C pending analysis.

Analytical methods

150 μL of plasma were mixed with 15μL of internal standard TCH18, a CPO compound with a linker of seven methylenes. Then, 285μL of methanol were added and vortex-mixed for 1 min. After centrifugation at 40000 rpm for 10 min, the organic layer was transferred to fresh glass test tubes, filtered and evaporated to dryness (Vacuum Evaporation System, Labconco, Kansas City, MO) and reconstituted with 80 μL of mobile phase. JS403 amount was determined by using a high-performance liquid chromatography (HPLC) system (Waters 2695 Separation Module) with a mass-spectrometer (Waters Micro-mass ZQ, Waters Corporation, Milford, MA). The HPLC-MS conditions were as follows: Xterra MS C18, 3.5μm,100A, 100x2.1mm column (Waters), an isocratic mobile phase, methanol:water:50mM ammonium formate buffer in water titrated with formic acid to pH=3.8-3.9 (57:23:20 v/v/v), flow rate of 0.2 mL/min at 45°C.

Pharmacokinetic (PK) analysis

Noncompartmental pharmacokinetic analysis was performed using WinNonlin software (version 5.1, Pharsight, Mountain View, CA).

Statistical analysis

All values are expressed as mean ± standard deviation mean (SD). To determine statistically significant differences among the experimental groups, t-test or one-way ANOVA, followed by Tukey’s test, was used. A p value less than 0.05 were termed significant.

RESULTS

Effect of various chitosan with different chain length on JS403 transport across Caco-2 monolayer

The effect of three different chitosans on the permeability coefficient (Papp) of JS403 when screened in Caco-2 cell model presented in Figure 6. The chitosans, listed in Table 1, varied in their average molecular weight, i.e. in their chain length, but shared the same degree of deacetylation of 80%. Shorter and longer chain lengths have shown significant enhancing permeability properties. Since shorter chain length chitosans displayed favorable viscosity, synthesis of future chitosans was done in the order of 10^6g/mol.

N-trimethyl chitosan derivatives

Library of N-trimethyl chitosan derivatives synthesis and characterization: A library of 9 N-trimethyl chitosan (TMC) derivatives was synthesized varying in the chain length, degree
of deacetylation and degree of trimethylation. For all TMCs, the counter-ion was Cl- and all were stable at room temperature and light. Table 2 depicts the specifications regarding each polymer.

N-trimethyl chitosan derivatives in-vitro permeability study: Figures 7-8 show the permeability enhancing properties of each TMC group, categorized by their average molecular weight, degree of deacetylation and trimethylation. TMC with a high degree of deacetylation – 95%, showed no permeability enhancing properties in both chain lengths and all degrees of N-trimethylation (Figure 7). When TMC derivatives with a lower degree of deacetylation – 85% - were tested, apart from KC23, all exhibited enhancing properties of some sort. KC13, with 20,000 gr/mol chain length and 66% degree of trimethylation showed the best enhancement properties.

On the other hand, KC23 with a 50,000 gr/mol chain length caused a significant decrease. Since lower degree of deacetylation – 85%, shorter chain length (20,000 gr/mol) and high degree of trimethylation seemed to portray favorable enhancing properties, synthesis of a novel TMC derivatives was done with that features.

N-methylated hydroxypropyl chitosan derivatives

N-methylated hydroxypropyl chitosan derivatives in-vitro permeability study: Permeability enhancing effect of N-methylated hydroxypropyl chitosan derivatives (KHC) was evaluated in Caco-2 model as presented in Figure 9. KHC2, the derivative with the highest degree of N-trimethylation content (71%), showed 10.5-fold improvement in JS403 permeability, the best significant enhancement so far.

The effect of N-trimethyl chitosan derivatives on atenolol in-vitro permeability study: The effect of the chosen derivatives, KC13 and KHC2 on permeability coefficient of a different class III model drug, atenolol, was assessed in Caco-2 cell model. The findings showed significantly permeability enhancement of 3.5-fold and 10-fold caused by KC13 and KHC2 respectively. These results fit perfectly with JS403 finding.

The effect of PC on JS403 and atenolol in-vitro permeability study: In this study, PC served as a positive control for paracellular enhancer and model reliability. The permeability coefficient of JS403 and atenolol was examined without and in PC presence in Caco-2 model. As expected, the permeability of both drugs was significantly increased.

Table 2: Library of N-trimethyl chitosans examined in Caco-2 study.

<table>
<thead>
<tr>
<th>TMC derivative Name</th>
<th>Degree of Deacetylation</th>
<th>Molecular Weight (gr/mol)</th>
<th>Content of trimethylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>KC12</td>
<td>85%</td>
<td>20,000</td>
<td>52%</td>
</tr>
<tr>
<td>KC13</td>
<td>85%</td>
<td>20,000</td>
<td>66%</td>
</tr>
<tr>
<td>KC21</td>
<td>85%</td>
<td>50,000</td>
<td>32%</td>
</tr>
<tr>
<td>KC22</td>
<td>85%</td>
<td>50,000</td>
<td>40%</td>
</tr>
<tr>
<td>KC23</td>
<td>85%</td>
<td>50,000</td>
<td>57%</td>
</tr>
<tr>
<td>KC-3-1</td>
<td>95%</td>
<td>20,000</td>
<td>38%</td>
</tr>
<tr>
<td>KC-4-1</td>
<td>95%</td>
<td>50,000</td>
<td>33%</td>
</tr>
<tr>
<td>KC-4-2</td>
<td>95%</td>
<td>50,000</td>
<td>64%</td>
</tr>
<tr>
<td>KC-4-3</td>
<td>95%</td>
<td>50,000</td>
<td>79%</td>
</tr>
</tbody>
</table>

Figure 6: JS403 permeation through Caco-2 cells without and in the presence of chitosans which varied in their average molecular weight. JS403 concentrations is 0.01% w/v, chitosan was 0.005 %w/v. n=3. (*) A significant difference from JS403 alone (p<0.05).

Figure 7: JS403 permeation through Caco-2 cells without and in the presence of TMC derivatives. degree of deacetylation 95%. JS403 concentrations is 0.01% w/v, TMC derivatives were 0.005 %w/v. n=3.

Figure 8: JS403 permeation through Caco-2 cells without and in the presence of TMC derivatives. degree of deacetylation 85%. JS403 concentrations is 0.01% w/v, TMC derivatives were 0.005 %w/v. n=3. (*) A significant difference from JS403 alone (p<0.05).

Figure 9: JS403 permeation through Caco-2 cells without and in the presence of KHC derivatives. n=3, JS403 concentrations is 0.01% w/v and KHC derivatives were 0.005 %w/v. (*) A significant difference from JS403 alone (p<0.05).
The oral bioavailability of JS403 by co-administration with various chitosan derivatives. The motivation to pursue this systematic study was first to improve the oral bioavailability of the CPO making it an effective anti-metastatic oral treatment. In addition, to enrich the knowledge base regarding the impact of chitosan derivatives as gentle absorption enhancers for other APIs from the BCS III family. The chitosan derivatives tested in the current research were selected according to previous reports [14]. In addition, certain novel derivatives were synthesized based on intelligent design. The current information regarding the in-vivo utilization of TMC derivatives are sparse thus this additional systematic evaluation is required.

To perform this investigation, a library of 11 TMC derivatives in a different range of parameter was synthesized. In order to identify the optimal parameters to enhance JS403 intestinal permeability the TMCs were coadministered with the CPO and the impact on the permeability was determined by using the Caco2 monolayer assay.

The first parameter investigated was chitosan chain length (MW). Three different chain lengths were studied but only two chain lengths had noteworthy impact on JS403 permeation. While short ($7 \times 10^4$ gr/mol) and long ($2 \times 10^6$ gr/mol) chain lengths increased JS403 permeation more prominently, the medium ($7.5 \times 10^5$ gr/mol) chain length elevated permeation but in a non-significant matter. Investigating this important parameter raised the issue of viscosity, where elevation of the molecular weight is associated with increased viscosity. Since high viscosity is not applicable for drug delivery, these findings indicated that it is preferable to synthesize short chain length chitosan in the order of $10^4$ gr/mol.

Another important parameter that was examined is the optimal degree of de-acetylation and trimethylation. For that, a 9 TMC derivatives library was synthesized with chain length in order of $10^4$ gr/mol, in accordance with the previous results. All TMC with a high degree of deacetylation, 95%, had no significant enhancing effect on JS403 permeation. This implies that such high degree of deacetylation hinders the enhancing properties for JS403. This finding may result from excessive charge density that impairs the chitosan ability to interact with the epithelial membrane surface. Conversely, most of the TMC derivatives group with a lower degree of deacetylation- 85%, showed enhancing properties of varying power.

The effect of N-trimethyl chitosan derivatives on JS403 in-vivo absorption study: Plasma concentration time profiles for JS403 following oral administration of JS403 with chitosan derivatives: KC13, KHC2 to rats are depicted in Figure 11. In agreement with the in-vitro results, Oral administration of JS403-KC13 and JS403-KHC2 resulted in significantly increase of 2-fold in AUC values as compared to the oral administration of JS403 alone (Table 4).

**DISCUSSION**

The CPO JS403 is a promising novel pharmaceutical entity that has shown efficacy in inhibiting cancer promoting enzymes in vitro and metastasis formation in vivo [2]. As a BCS class III compound it exhibits low oral bioavailability. The aim of the current investigation is to utilize the "pharmaceutical approach" to enhance

Table 3: Library of N-trimethyl hydroxyspropyl chitosan’s examined in Caco-2 study.

<table>
<thead>
<tr>
<th>Group name</th>
<th>AUCinf (h*$\mu$g/mL)</th>
<th>Cmax (µg/mL)</th>
<th>t 1/2 (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JS403</td>
<td>10.2±4.7</td>
<td>3±0.3</td>
<td>5.53±0.7</td>
</tr>
<tr>
<td>JS403+KHC</td>
<td>23.2±7.9</td>
<td>7.33±3.53</td>
<td>4.84±1.7</td>
</tr>
<tr>
<td>JS403+KHC2</td>
<td>21.5±4.5</td>
<td>5.59±1.4</td>
<td>2.61±1.04</td>
</tr>
</tbody>
</table>

Table 4: AUC, Cmax and t1/2 values (mean ± SD) obtained following single oral administration of JS403 (300 mg/kg) compared to single oral co-administration of JS403 with KHC and KC13 (100 mg/kg) to rats (n=4). (*) A significant difference (p<0.05) compare to group single oral administration of JS403.

<table>
<thead>
<tr>
<th>TMC derivative Name</th>
<th>Deacetylation degree</th>
<th>Molecular weight (gr/mol)</th>
<th>Content of trimethylation</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHC1</td>
<td>85%</td>
<td>20,000</td>
<td>42%</td>
</tr>
<tr>
<td>KHC2</td>
<td>85%</td>
<td>20,000</td>
<td>71%</td>
</tr>
</tbody>
</table>

significantly elevated with PC presence, as can be seen in Figure 10.

The effect of N-trimethyl chitosan derivatives on JS403 in-vivo absorption study: Plasma concentration time profiles for JS403 following oral administration of JS403 with chitosan derivatives: KC13, KHC2 to rats are depicted in Figure 11. In agreement with the in-vitro results, Oral administration of JS403-KC13 and JS403-KHC2 resulted in significantly increase of 2-fold in AUC values as compared to the oral administration of JS403 alone (Table 4).
impact of lipophilicity of several derivatives of N-alkyl-chitosan on permeation enhancement in bronchial epithelium in-vitro [15]. They suggested that increasing the polymer lipophilicity could augment the permeation enhancement. Hence, in this study, a library of two novel chitosan derivatives- KHC was synthesized with all the optimal parameters, determined so far, and with a higher degree of lipophilicity by adding hydroxypropyl. Indeed, the novel derivative, KHC-2, have shown favorable effect over TMC derivatives on JS403 permeation enhancement. The greater ability of KHC2 to enhance JS403 permeability compare to KC13 may also stems from higher degree of trimethylation and the conformational modifications associated with this modification. This reasoning is along the same line that was stated previously by Dewald Smyman et al. that decrease in flexibility of TMC compare to chitosan can arise due to altered chitosan conformation [16].

The main purpose of this study was to investigate the effects of chitosan parameters on JS403 permeability. JS403 portrays part within BCS class III molecules. Therefore, it was important to examine if the anionic charge of JS403 in physiological fluids had electrostatic influence on the chitosan derivatives permeation enhancement capacity by comparing it to a positively charged BCS III compound such as atenolol [9,17]. The permeability of atenolol in the absence and presence of KC13 and KHC2 derivatives was found to be affected in the same way as JS403. These results corroborate the conclusion that the enhancement ability of the derivatives as observed in this study is not specific only to JS403 and probably can apply to a wider spectrum of class III molecules. This may also imply that the impact of the chitosan absorption enhancers is affecting the width of the TJ in a manner that is not dependent on the co-administered API.

In general, there may be a big gap between in-vitro permeability findings and the ultimate utilization of these findings in-vivo when dealing with the oral bioavailability. At the whole animal pharmacokinetic absorption study multithreaded biological processes occurs that may affect the eventual outcome. On the other hand, the enterocyte monolayer that covers the intestinal surface is the major barrier for BCS III compounds. Thus, assessing this barrier behavior in the presence of the tested API and the co-administered enhancer provide realistic evaluation of what would be the impact of affecting the enterocyte monolayer permeability (as in the case of Caco2 model), and the consequent overall bioavailability findings. This is because when dealing in the case of consecutive barriers cascade the rate determinant is the slowest process, which in the current case is the kinetics of crossing the enterocyte layer. Therefore, although generally it may be difficult to produce a passable in-vitro - in-vivo correlation (IVIVC), the rationale of conducting the in-vitro permeability study that is used to provide a predictive model for the in-vivo absorption outcome is quite reasonable, particularly, in the case of BCS III APIs [18].

According this rational the impact of the tested potential enhancers was studied also in-vitro. Indeed, following JS403 oral administration alone and combined with the leading derivatives KC13 and KHC2, the in-vitro findings provided a similar picture to the in-vitro predication. The results showed a statistically significant enhancement of 2-fold in JS403 AUC when given with KC13 and KHC2 derivatives, as correlate with the in-vitro results, but not in the same proportion. The differences in the proportion of KHC2 enhancement between the two models result most probably from the fact that the cell culture cannot fully simulate the additional processes that are associated the absorption process after oral administration into living body. Specifically, the in-vitro monolayer model has a static mode that does not represent the processes associated with substances transport along the intestinal tract. It is important to note that the in-vitro studies in the current investigation where conducted in freely moving rats' and the API-enhancer combination was given by oral gavage. This administration modality mimics more closely the utilization of such combination in the clinical setting. In the past the in-vitro evaluations of chitosan impact on intestinal bioavailability where conducted following intra-duodenal administration [19,20]. The intra-duodenal administration has it own rationale but it for sure differ from what would ultimately happen following oral administration of the formulation. Needless to mention that intra-duodenal necessitate abdominal surgery that by itself may affect the investigated pharmacokinetics.

Another permeability enhancer which is known for its strong influence to enlarge TJ width is PC. Even though, PC is not clinically relevant due to safety concerns associated with the aggressive TJ opening. It was used in the current investigation in order to validate that the actual penetration pathway of the tested BCSIII APIs is related to the TJ width. Therefore, their co-administration with PC was used as a positive control for paracellular pathway enhancer. Indeed, the permeability of both atenolol and JS403 in the presence of PC has been significantly increased. Thus, confirming one of the investigation’s hypothesizes regarding the intestinal permeability mechanism of these BCS III APIs.

In conclusion, the challenge of increasing the paracellular permeability of JS403 as BCS III APIs is of importance due to their limited bioavailability restricted by the small diffusion space confined to the TJs. The potential enhancers have limited range of permeability enhancement as their impact has to be reversible and noninvasive which limits the fierceness of altering the TJ sites. As delineated in this work, chemical modifications of chitosan had quite modest impact on the permeability of JS403. Actually, in order to have immense impact on the degree of oral bioavailability the enhancer should be able to redirect the absorption mechanism from paracellular to transcellular where the absorptive surface is many folds larger. In general, the advantages of the pharmaceutical approach in enhancing bioavailability of BCS III compounds result from the fact that the API remains chemically untouched which makes it more accessible for advanced clinical utilization.

The investigation highlighted that KC13 and KHC2 chitosan derivatives can probably be used safely as absorption enhancer additives in formulation aimed to improve oral bioavailability of the BCS III APIs with physicochemical properties like JS403. Certain guidelines of methodologies to improve the chitosan derivatives absorption enhancing properties such as chain length, degree of acetylation, trimethylation and lipophilicity that were evaluated in the current research should be taken into consideration in future application and investigation of this approach.

ACKNOWLEDGEMENT

The authors would like to acknowledge the financial support of this international “lighthouse” project funded by Fraunhofer Society, Germany and Sir Zelman Cowen university fund HUJI.
REFERENCES


